PLANO, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced the completion of the previously announced sale of its Electrochem business to Ultralife Corporation for $50 million in cash. Integer will use the proceeds from the sale to pay down outstanding debt. “With the divestiture of Electrochem, Integer is now a pure-play medical technology company with additional capital to d ...

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.43 in the third quarter of 2024, which improved 10.9% year over year. The figure topped the Zacks Consensus Estimate by 5.15%.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP EPS for the quarter was $1.01, reflecting an improvement of 21.7% year over year.Stay up-to-date with all quarterly releases: See Zacks Earnings Ca ...

财务数据和关键指标变化 - 第三季度销售额为4.31亿美元，同比增长9%，年初至今销售额为12.67亿美元，同比增长10% [6][10][8] - 调整后的营业收入同比增长17%，年初至今调整后的营业收入增长23% [6][9] - 调整后的净收入为5000万美元，同比增长11% [11] - 调整后的每股收益为1.43美元，同比增长21% [11][12] 各条业务线数据和关键指标变化 - 心血管产品线在过去四个季度的销售额同比增长15% [11] - 心脏节律管理和神经调节产品线在过去四个季度的销售额同比增长7% [11] - 心血管产品线的增长主要得益于电生理和结构性心脏的新产品 [11] 各个市场数据和关键指标变化 - 预计2024年销售额将增长10%至11%，有机增长率为7%至8% [14][15] - 新兴市场的客户需求强劲，预计将推动第四季度的销售增长 [22][28] 公司战略和发展方向和行业竞争 - 公司计划通过剥离非医疗业务，专注于医疗技术领域，预计将产生5000万美元的现金流 [7] - 公司目标是实现销售增长超过市场200个基点，调整后的营业收入增长速度是销售增长的两倍 [19][15] 管理层对经营环境和未来前景的评论 - 管理层对未来的展望持乐观态度，预计将继续实现强劲的销售增长和利润增长 [19][6] - 管理层提到，尽管面临一些短期挑战，如飓风影响，但整体业务表现良好，预计第四季度将恢复增长 [20][29] 其他重要信息 - 公司在第三季度的运营现金流为7200万美元，同比增长14% [13] - 净总债务为10.55亿美元，较第二季度减少4100万美元 [14] 问答环节所有提问和回答 问题: 关于第三季度有机增长趋势的变化 - 管理层表示，第三季度的有机增长率为4%，主要受到心脏节律管理产品线需求下降和飓风影响的影响 [20][21] 问题: 关于新任高管的角色变化 - 管理层强调新任高管将继续执行公司的战略，推动销售增长和利润增长 [24] 问题: 关于电生理业务的增长趋势 - 管理层表示，电生理业务仍在持续增长，预计将继续受益于新产品的推出 [26][27] 问题: 关于第四季度的有机增长加速预期 - 管理层预计第四季度的有机增长将加速，特别是在心血管和神经调节产品线 [28] 问题: 关于飓风影响的持续性 - 管理层指出，飓风的影响主要是成本压力，预计不会对第四季度的销售产生重大影响 [29] 问题: 关于2025年的市场预期 - 管理层表示，预计2025年将继续保持正常的市场增长，目标是实现有机增长超过市场200个基点 [32]

Integer (ITGR) reported $431.42 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 6.6%. EPS of $1.43 for the same period compares to $1.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $443.19 million, representing a surprise of -2.66%. The company delivered an EPS surprise of +5.15%, with the consensus EPS estimate being $1.36.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

业绩总结 - 2024年第三季度销售额为17.07亿至17.27亿美元，同比增长9%[5] - 调整后营业收入同比增长17%，预计2024年调整后营业收入为2.8亿至2.88亿美元，同比增长18%至22%[5] - 调整后每股收益（EPS）为5.24至5.43美元，同比增长14%至18%[5] - 自由现金流预计为9000万至1亿美元，同比增长49%至65%[5] - 2024年第三季度销售额同比增长9%，年初至今增长10%[27] - 调整后的营业收入同比增长17%，年初至今增长23%[27] - 调整后的每股收益（EPS）同比增长11%，年初至今增长21%[27] - 2024年第三季度净收入为36,282千美元，较2023年同期增长了约8.5%[58] - 2024年截至目前的净收入为107,876千美元，较2023年同期增长了约12.0%[59] 用户数据 - 2024年第三季度债务杠杆比率为3.0x，处于战略目标的中位数范围内[5] - 2024年有效税率预计在18.0%至19.0%之间[35] - 2024年第一季度有效税率为19.5%[56] - 2024年第二季度有效税率为19.5%[57] 未来展望 - 2024年销售额预计增长10%至11%，调整后营业收入和每股收益的中位数上调[5] - 2024年有机销售增长预计为7%至8%[24] - 2024年预计第四季度销售额将较第三季度增长，受新产品推出和客户增长推动[24] - 公司预计2024年整体销售将受到新产品和市场需求的推动[48] 新产品和新技术研发 - 预计2024年Cardio & Vascular产品线的销售将实现低双位数的同比增长[48] - 预计2024年CRM & Neuromodulation产品线的销售将实现高单位数的同比增长[51] - 2024年Advanced Surgical & Orthopedics产品线的销售将同比下降约个位数[53] 财务数据 - 2024年第一季度销售额为407,796千美元，较2023年同期的364,671千美元增长11.8%[56] - 2024年第一季度毛利为108,273千美元，毛利率为26.6%[56] - 2024年第一季度运营收入为69,572千美元，运营利润率为17.1%[56] - 2024年第二季度销售额为427,886千美元，较2023年同期的389,678千美元增长9.8%[57] - 2024年第二季度毛利为117,377千美元，毛利率为27.4%[57] - 2024年第二季度运营收入为62,883千美元，运营利润率为14.7%[57] - 2024年第三季度销售额为431,417千美元，同比增长8.7%[58] - 2024年第三季度毛利为116,568千美元，毛利率为27.0%[58] - 2024年第三季度运营收入为58,557千美元，运营利润率为13.6%[58] - 2024年截至目前的销售额为1,267,099千美元，同比增长10.1%[59] - 2024年截至目前的毛利为342,218千美元，毛利率为27.0%[59] - 2024年截至目前的运营收入为191,012千美元，运营利润率为15.0%[59] - 2024年截至目前的稀释每股收益为0.95美元，较2023年同期增长了约8.0%[59]

Integer (ITGR) came out with quarterly earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.15%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.24 per share when it actually produced earnings of $1.30, delivering a surprise of 4.84%.Over the last four qu ...

EXHIBIT 99.1 Integer Holdings Corporation Reports Third Quarter 2024 Results ~ Continued strong performance with 3Q24 financial results ~ ~ Raising midpoint of 2024 operating profit and EPS outlook ~ PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three and nine months ended September 27, 2024. Our previously announced sale of the Electrochem business for $50 million in cash remains on track and is expected to close later this month. E ...

Wall Street analysts expect Integer (ITGR) to post quarterly earnings of $1.36 per share in its upcoming report, which indicates a year-over-year increase of 7.1%. Revenues are expected to be $443.19 million, up 9.5% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a comp ...

Integer Holdings (ITGR) witnessed strong momentum year to date. Shares of the company have gained 30.5% against the 0.1% decline of the industry in the same time frame. The S&P 500 Composite has risen 19.6% during the same period. Image Source: Zacks Investment Research With healthy fundamentals and strong growth opportunities, this Zacks Rank #4 (Sell) company appears to be a solid wealth creator for its investors at the moment. Plano, TX-based Integer Holdings manufactures and develops medical devices and ...

PLANO, Texas, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company"), a leading medical device contract development and manufacturing organization, today notified holders of its 2.125% Convertible Senior Notes due 2028 (the "Notes") that the Notes are convertible, at the option of the holders (the "Conversion Option") beginning on October 1, 2024, and ending at the close of business on December 31, 2024. The Notes are convertible into cash, up to the princip ...